BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 28467214)

  • 1. Evaluation of the Afirma Gene Expression Classifier in Repeat Indeterminate Thyroid Nodules.
    Harrison G; Sosa JA; Jiang X
    Arch Pathol Lab Med; 2017 Jul; 141(7):985-989. PubMed ID: 28467214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Afirma gene expression classifier on cytopathology diagnosis and rate of thyroidectomy.
    Sacks WL; Bose S; Zumsteg ZS; Wong R; Shiao SL; Braunstein GD; Ho AS
    Cancer Cytopathol; 2016 Oct; 124(10):722-728. PubMed ID: 27347838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The first Canadian experience with the Afirma® gene expression classifier test.
    Kay-Rivest E; Tibbo J; Bouhabel S; Tamilia M; Leboeuf R; Forest VI; Hier MP; Savoury L; Payne RJ
    J Otolaryngol Head Neck Surg; 2017 Apr; 46(1):25. PubMed ID: 28372589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship Between Sonographic Characteristics and Afirma Gene Expression Classifier Results in Thyroid Nodules With Indeterminate Fine-Needle Aspiration Cytopathology.
    Zhu QL; Faquin WC; Samir AE
    AJR Am J Roentgenol; 2015 Oct; 205(4):861-5. PubMed ID: 26397337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules.
    McIver B; Castro MR; Morris JC; Bernet V; Smallridge R; Henry M; Kosok L; Reddi H
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4069-77. PubMed ID: 24780044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeat Fine Needle Aspiration Cytology Refines the Selection of Thyroid Nodules for Afirma Gene Expression Classifier Testing.
    Nishino M; Mateo R; Kilim H; Feldman A; Elliott A; Shen C; Hasselgren PO; Wang H; Hartzband P; Hennessey JV
    Thyroid; 2021 Aug; 31(8):1253-1263. PubMed ID: 33813868
    [No Abstract]   [Full Text] [Related]  

  • 7. Multicenter clinical experience with the Afirma gene expression classifier.
    Alexander EK; Schorr M; Klopper J; Kim C; Sipos J; Nabhan F; Parker C; Steward DL; Mandel SJ; Haugen BR
    J Clin Endocrinol Metab; 2014 Jan; 99(1):119-25. PubMed ID: 24152684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Afirma Gene Sequencing Classifier Compared with Gene Expression Classifier in Indeterminate Thyroid Nodules.
    Endo M; Nabhan F; Porter K; Roll K; Shirley LA; Azaryan I; Tonkovich D; Perlick J; Ryan LE; Khawaja R; Meng S; Phay JE; Ringel MD; Sipos JA
    Thyroid; 2019 Aug; 29(8):1115-1124. PubMed ID: 31154940
    [No Abstract]   [Full Text] [Related]  

  • 9. Implications of a suspicious afirma test result in thyroid fine-needle aspiration cytology: an institutional experience.
    Lastra RR; Pramick MR; Crammer CJ; LiVolsi VA; Baloch ZW
    Cancer Cytopathol; 2014 Oct; 122(10):737-44. PubMed ID: 25123499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes.
    Baca SC; Wong KS; Strickland KC; Heller HT; Kim MI; Barletta JA; Cibas ES; Krane JF; Marqusee E; Angell TE
    Cancer Cytopathol; 2017 May; 125(5):313-322. PubMed ID: 28152275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of the Afirma genomic sequencing classifier versus gene expression classifier: An institutional experience.
    Wei S; Veloski C; Sharda P; Ehya H
    Cancer Cytopathol; 2019 Nov; 127(11):720-724. PubMed ID: 31536167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of the Afirma Xpression Atlas for cytologically indeterminate, Afirma Genomic Sequencing Classifier suspicious thyroid nodules: Clinicopathologic analysis with postoperative molecular testing.
    Munoz-Zuluaga CA; Heymann JJ; Solomon JP; Patel A; Siddiqui MT; Scognamiglio T; Gokozan HN
    Am J Clin Pathol; 2024 May; 161(5):463-468. PubMed ID: 38104250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Independent Comparison of the Afirma Genomic Sequencing Classifier and Gene Expression Classifier for Cytologically Indeterminate Thyroid Nodules.
    Angell TE; Heller HT; Cibas ES; Barletta JA; Kim MI; Krane JF; Marqusee E
    Thyroid; 2019 May; 29(5):650-656. PubMed ID: 30803388
    [No Abstract]   [Full Text] [Related]  

  • 14. Thyroid nodule molecular profiling: The clinical utility of Afirma Xpression Atlas for nodules with Afirma Genomic Sequencing Classifier-suspicious results.
    Babazadeh NT; Sinclair TJ; Krishnamurthy V; Jin J; Heiden KB; Shin J; Berber E; Siperstein A
    Surgery; 2022 Jan; 171(1):155-159. PubMed ID: 34924179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. UTILITY OF AFIRMA GENE EXPRESSION CLASSIFIER FOR EVALUATION OF INDETERMINATE THYROID NODULES AND CORRELATION WITH ULTRASOUND RISK ASSESSMENT: SINGLE INSTITUTIONAL EXPERIENCE.
    Sultan R; Levy S; Sulanc E; Honasoge M; Rao SD
    Endocr Pract; 2020 May; 26(5):543-551. PubMed ID: 31968199
    [No Abstract]   [Full Text] [Related]  

  • 16. Hurthle cell predominance impacts results of Afirma gene expression classifier and ThyroSeq molecular panel performance in indeterminate thyroid nodules.
    Parajuli S; Jug R; Ahmadi S; Jiang XS
    Diagn Cytopathol; 2019 Nov; 47(11):1177-1183. PubMed ID: 31348619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of Afirma genomic sequencing classifier vs gene expression classifier in Bethesda category III thyroid nodules: An institutional experience.
    Zhang L; Smola B; Lew M; Pang J; Cantley R; Pantanowitz L; Heider A; Jing X
    Diagn Cytopathol; 2021 Aug; 49(8):921-927. PubMed ID: 34021740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of Afirma Gene Sequencing Classifier versus Gene Expression Classifier in thyroid nodules with indeterminate cytology.
    Yang Z; Zhang T; Layfield L; Esebua M
    J Am Soc Cytopathol; 2022; 11(2):74-78. PubMed ID: 34366280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular testing for indeterminate thyroid nodules: Performance of the Afirma gene expression classifier and ThyroSeq panel.
    Jug RC; Datto MB; Jiang XS
    Cancer Cytopathol; 2018 Jul; 126(7):471-480. PubMed ID: 29637728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How "suspicious" is that nodule? Review of "suspicious" Afirma gene expression classifier in high risk thyroid nodules.
    Roychoudhury S; Klein M; Souza F; Gimenez C; Laser A; Shaheen Cocker R; Chau K; Das K
    Diagn Cytopathol; 2017 Apr; 45(4):308-311. PubMed ID: 28188700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.